Book contents
- Androgens in Gynecological Practice
- Androgens in Gynecological Practice
- Copyright page
- Contents
- About the editors
- Dedication
- Contributors
- Preface
- Section 1 Managing the basics
- Section 2 The scientific essentials
- 5 The androgen receptor: basic structure and function
- 6 Androgens in postmenopausal women: Their practically exclusive intracrine formation and inactivation in peripheral tissues
- 7 Diagnostic criteria of polycystic ovary syndrome
- 8 Androgen effects on the skin
- 9 Polycystic ovary syndrome and cardiovascular risk
- 10 Effects of androgens on female genital tract
- Section 3 Learning from the extremes
- Section 4 The tool kit
- Index
- Plate Section
- References
6 - Androgens in postmenopausal women: Their practically exclusive intracrine formation and inactivation in peripheral tissues
from Section 2 - The scientific essentials
Published online by Cambridge University Press: 05 July 2015
Book contents
- Androgens in Gynecological Practice
- Androgens in Gynecological Practice
- Copyright page
- Contents
- About the editors
- Dedication
- Contributors
- Preface
- Section 1 Managing the basics
- Section 2 The scientific essentials
- 5 The androgen receptor: basic structure and function
- 6 Androgens in postmenopausal women: Their practically exclusive intracrine formation and inactivation in peripheral tissues
- 7 Diagnostic criteria of polycystic ovary syndrome
- 8 Androgen effects on the skin
- 9 Polycystic ovary syndrome and cardiovascular risk
- 10 Effects of androgens on female genital tract
- Section 3 Learning from the extremes
- Section 4 The tool kit
- Index
- Plate Section
- References
Summary
A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
- Type
- Chapter
- Information
- Androgens in Gynecological Practice , pp. 64 - 73Publisher: Cambridge University PressPrint publication year: 2015
References
1.Labrie, F, Bélanger, A, Bélanger, P, et al. Androgen glucuronides, instead of testosterone, as the new markers of androgenic activity in women. J Steroid Biochem Mol Biol 2006;99(4–5):182–8.Google Scholar
3.Labrie, F, Cusan, L, Gomez, JL, et al. Comparable amounts of sex steroids are made outside the gonads in men and women: strong lesson for hormone therapy of prostate and breast cancer. J Steroid Biochem Mol Biol 2009;113(1–2):52–6.CrossRefGoogle ScholarPubMed
4.Labrie, F, Martel, C, Balser, J. Wide distribution of the serum dehydroepiandrosterone and sex steroid levels in postmenopausal women: role of the ovary? Menopause 2011;18(1):30–43.Google Scholar
5.NAMS – The North American Menopause Society. The role of testosterone therapy in postmenopausal women: position statement of The North American Menopause Society. Menopause 2005;12(5):496–511; quiz 649.Google Scholar
6.Rosner, W, Auchus, RJ, Azziz, R, et al. Position statement: utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement. J Clin Endocrinol Metab 2007;92(2):405–13.CrossRefGoogle ScholarPubMed
7.Rosner, W, Hankinson, SE, Sluss, PM, et al. Challenges to the measurement of estradiol: an endocrine society position statement. J Clin Endocrinol Metab 2013;98(4):1376–87.Google Scholar
8.Taieb, J, Mathian, B, Millot, F, et al. Testosterone measured by 10 immunoassays and by isotope-dilution gas chromatography-mass spectrometry in sera from 116 men, women, and children. Clin Chem 2003;49(8):1381–95.CrossRefGoogle ScholarPubMed
9.Moal, V, Mathieu, E, Reynier, P, et al. Low serum testosterone assayed by liquid chromatography-tandem mass spectrometry. Comparison with five immunoassay techniques. Clin Chim Acta 2007;386(1–2):12–19.Google Scholar
10.Sikaris, K, McLachlan, RI, Kazlauskas, R, et al. Reproductive hormone reference intervals for healthy fertile young men: evaluation of automated platform assays. J Clin Endocrinol Metab 2005;90(11):5928–36.CrossRefGoogle ScholarPubMed
11.Shackleton, C. Clinical steroid mass spectrometry: a 45-year history culminating in HPLC-MS/MS becoming an essential tool for patient diagnosis. J Steroid Biochem Mol Biol 2010;121(3–5):481–90.CrossRefGoogle ScholarPubMed
12.Ke, Y., Bertin, J., et al. (2014). “A Sensitive, Simple and Robust LC-MS/MS Method for the Simultaneous Quantification of Seven Androgen- and Estrogen-Related Steroids in Postmenopausal Serum.” J Steroid Biochem Mol Biol 144: 523–534.Google Scholar
13.Ke, Y., Gonthier, R., et al. (2015). “A rapid and sensitive UPLC-MS/MS method for the simultaneous quantification of serum androsterone glucuronide, etiocholanolone glucuronide, and androstan-3alpha, 17beta diol 17-glucuronide in postmenopausal women.” JSBMB: In press.Google Scholar
14.Dury, A. Y., Ke, Y., et al. (2015). “Validated LC-MS/MS simultaneous assay of five sex steroid/neurosteroid-related sulfates in human serum.” JSBMB 149C: 1–10.Google Scholar
15.Labrie, F., Ke, Y., et al. (2015). “Why both LC-MS/MS and FDA-compliant validation are essential for accurate estrogen assays?” J Ster Biochem Mol Biol. 149C: 89–91.Google Scholar
16.Hsing, AW, Stanczyk, FZ, Belanger, A, et al. Reproducibility of serum sex steroid assays in men by RIA and mass spectrometry. Cancer Epidemiol Biomarkers Prev 2007;16(5):1004–8.CrossRefGoogle Scholar
17.Labrie, F. DHEA after menopause – sole source of sex steroids and potential sex steroid deficiency treatment. Menopause Management 2010;19:14–24.Google Scholar
18.Labrie, F, Labrie, C. DHEA and intracrinology at menopause, a positive choice for evolution of the human species. Climacteric. 2013;16(2):205–13.Google Scholar
19.Labrie, C, Bélanger, A, Labrie, F. Androgenic activity of dehydroepiandrosterone and androstenedione in the rat ventral prostate. Endocrinology 1988;123(3):1412–17.CrossRefGoogle ScholarPubMed
20.Labrie, F, Dupont, A, Bélanger, A. Complete androgen blockade for the treatment of prostate cancer. In: de Vita, VT, Hellman, S, Rosenberg, SA, editors. Important Advances in Oncology. Philadelphia: J.B. Lippincott; 1985. pp. 193–217.Google Scholar
21.Labrie, F, Dupont, A, Bélanger, A, et al. New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen. Clin Invest Med 1982;5(4):267–75.Google Scholar
22.Crawford, ED, Eisenberger, MA, McLeod, DG, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989;321(7):419–24.CrossRefGoogle ScholarPubMed
23.Labrie, F, Bélanger, A, Cusan, L, et al. Antifertility effects of LHRH agonists in the male. J Androl 1980;1:209–28.Google Scholar
24.Baker, ME. Co-evolution of steroidogenic and steroid-inactivating enzymes and adrenal and sex steroid receptors. Mol Cell Endocrinol 2004;215(1–2):55–62.Google Scholar
25.Labrie, F, Luu-The, V, Bélanger, A, et al. Is DHEA a hormone? Starling Review. J Endocrinol 2005;187(2):169–96.Google Scholar
26.Luu-The, V. Assessment of steroidogenic pathways that do not require testosterone as intermediate. Horm Mol Biol Clin Invest 2011;5:161–5.Google Scholar
27.Labrie, F, Simard, J, Luu-The, V, et al. Structure, function and tissue-specific gene expression of 3b-hydroxysteroid dehydrogenase/5-ene-4-ene isomerase enzymes in classical and peripheral intracrine steroidogenic tissues. J Steroid Biochem Mol Biol 1992;43(8):805–26.CrossRefGoogle Scholar
28.Labrie, F, Sugimoto, Y, Luu-The, V, et al. Structure of human type II 5α-reductase gene. Endocrinology 1992;131(3):1571–3.Google Scholar
29.Labrie, Y, Durocher, F, Lachance, Y, et al. The human type II 17β-hydroxysteroid dehydrogenase gene encodes two alternatively-spliced messenger RNA species. DNA Cell Biol 1995;14(10):849–61.Google Scholar
30.Luu-The, V, Zhang, Y, Poirier, D, et al. Characteristics of human types 1, 2 and 3 17b-hydroxysteroid dehydrogenase activities: oxidation-reduction and inhibition. J Steroid Biochem Mol Biol 1995;55(5–6):581–7.CrossRefGoogle Scholar
31.Labrie, F, Simard, J, Luu-The, V, et al. The 3β-hydroxysteroid dehydrogenase/isomerase gene family: lessons from type II 3β-HSD congenital deficiency. Signal Transduction in Testicular Cells, Ernst Schering Research Foundation Workshop 1996;Suppl. 2:185–218.Google Scholar
32.Labrie, F, Luu-The, V, Lin, SX, et al. The key role of 17b-HSDs in sex steroid biology. Steroids 1997;62(1):148–58.Google Scholar
33.Longcope, C, Franz, C, Morello, C, et al. Steroid and gonadotropin levels in women during the peri-menopausal years. Maturitas 1986;8(3):189–96.Google Scholar
34.Burger, HG, Dudley, EC, Cui, J, et al. A prospective longitudinal study of serum testosterone dehydroepiandrosterone sulfate and sex hormone binding globulin levels through the menopause transition. J Clin Endocrinol Metab 2000;85(8):2832–8.Google Scholar
35.Rannevik, G, Jeppsson, S, Johnell, O, et al. A longitudinal study of the perimenopausal transition: altered profiles of steroid and pituitary hormones, SHBG and bone mineral density. Maturitas 1995;21(2):103–13.CrossRefGoogle ScholarPubMed
36.Labrie, F. Drug Insight: breast cancer prevention and tissue-targeted hormone replacement therapy. Nat Clin Pract Endocrinol Metab 2007;3(8):584–93.Google Scholar
37.Labrie, F, Luu-The, V, Labrie, C, et al. Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. Endocr Rev 2003;24(2):152–82.Google Scholar
38.Labrie, F, Bélanger, A, Cusan, L, et al. Marked decline in serum concentrations of adrenal C19 sex steroid precursors and conjugated androgen metabolites during aging. J Clin Endocrinol Metab 1997;82(8):2396–402.Google Scholar
39.Luu-The, V, Labrie, F. The intracrine sex steroid biosynthesis pathways. In: Martini, L, Chrousos, GP, Labrie, F, et al., editors. Neuroendocrinology, Pathological Situations and Diseases, Progress in Brain Research: Elsevier; 2010. pp. 177–92.Google Scholar
40.Couzinet, B, Meduri, G, Lecce, MG, et al. The postmenopausal ovary is not a major androgen-producing gland. J Clin Endocrinol Metab 2001;86(10):5060–6.Google Scholar
41.Abraham, GE, Lobotsky, J, Lloyd, CW. Metabolism of testosterone and androstenedione in normal and ovariectomized women. J Clin Invest; 1969;48(4):696–703.CrossRefGoogle ScholarPubMed
42.Jabara, S, Christenson, LK, Wang, CY, et al. Stromal cells of the human postmenopausal ovary display a distinctive biochemical and molecular phenotype. J Clin Endocrinol Metab 2003;88(1):484–92.Google Scholar
43.Cauley, JA, Gutai, JP, Kuller, LH, et al. The epidemiology of serum sex hormones in postmenopausal women. Am J Epidemiol 1989;129(6):1120–31.CrossRefGoogle ScholarPubMed
44.Nagamani, M, Urban, RJ. Expression of messenger ribonucleic acid encoding steroidogenic enzymes in postmenopausal ovaries. J Soc Gynecol Investig 2003;10(1):37–40.Google Scholar
45.Havelock, JC, Rainey, WE, Bradshaw, KD, et al. The post-menopausal ovary displays a unique pattern of steroidogenic enzyme expression. Hum Reprod 2006;21(1):309–17.Google Scholar
46.Spark, RF. Dehydroepiandrosterone: a springboard hormone for female sexuality. Fertil Steril 2002;77 Suppl 4:S19–25.CrossRefGoogle ScholarPubMed
47.Zumoff, B, Strain, GW, Miller, LK, et al. Twenty-four-hour mean plasma testosterone concentration declines with age in normal premenopausal women. J Clin Endocrinol Metab 1995;80(4):1429–30.Google Scholar
49.Tchernof, A, Labrie, F. Dehydroepiandrosterone, obesity and cardiovascular disease risk. A review of human studies. Eur J Endocrinol 2004;151(1):1–14.Google Scholar
50.Shifren, JL, Braunstein, GD, Simon, JA, et al. Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N Engl J Med 2000;343(10):682–8.CrossRefGoogle ScholarPubMed
51.Sherwin, BB, Gelfand, MM. The role of androgen in the maintenance of sexual functioning in oophorectomized women. Psychosom Med 1987;49(4):397–409.Google Scholar
52.Cameron, DR, Braunstein, GD. Androgen replacement therapy in women. Fertil Steril 2004;82(2):273–89.Google Scholar
53.Garland, CF, Friedlander, NJ, Barrett-Connor, E, et al. Sex hormones and postmenopausal breast cancer: a prospective study in an adult community. Am J Epidemiol 1992;135(11):1220–30.Google Scholar
54.Leiblum, S, Bachmann, G, Kemmann, E, et al. Vaginal atrophy in the postmenopausal women. The importance of sexual activity and hormones. JAMA 1983;249(16):2195–8.Google Scholar
55.Lipworth, L, Adami, HO, Trichopoulos, D, et al. Serum steroid hormone levels, sex hormone-binding globulin, and body mass index in the etiology of postmenopausal breast cancer. Epidemiology 1996;7(1):96–100.CrossRefGoogle ScholarPubMed
56.Davis, SR, McCloud, P, Strauss, BJ, et al. Testosterone enhances estradiol’s effects on postmenopausal bone density and sexuality. Maturitas 1995;21(3):227–36.CrossRefGoogle ScholarPubMed
57.Labrie, F, Bélanger, A, Cusan, L, et al. Physiological changes in dehydroepiandrosterone are not reflected by serum levels of active androgens and estrogens but of their metabolites: intracrinology. J Clin Endocrinol Metab 1997;82(8):2403–9.CrossRefGoogle Scholar
58.Poortman, J, Thijssen, JH, von Landeghem, AA, et al. Subcellular distribution of androgens and oestrogens in target tissue. J Steroid Biochem 1983;19(1C):939–45.Google Scholar
59.Bélanger, B, Bélanger, A, Labrie, F, et al. Comparison of residual C-19 steroids in plasma and prostatic tissue of human, rat and guinea pig after castration: unique importance of extratesticular androgens in men. J Steroid Biochem 1989;32(5):695–8.Google Scholar
60.Bélanger, A, Pelletier, G, Labrie, F, et al. Inactivation of androgens by UDP-glucuronosyltransferase enzymes in humans. Trends Endocrinol Metab 2003;14(10):473–9.Google Scholar
61.Zwicker, H, Rittmaster, RS. Androsterone sulfate: physiology and clinical significance in hirsute women. J Clin Endocrinol Metab 1993;76(1):112–16.Google Scholar
- 9
- Cited by